Roivant Sciences Ltd (ROIV) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Roivant Sciences Ltd stock $19.47, price $38.61, that is 49.6% below the price, quality 44 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.
How to read this chart
60‑month range $2.81 – $41.85 · fair‑value band $14.60 – $24.34 · the $38.61 price screens above the $19.47 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 14, 2026.
Follow Roivant Sciences in your weekly email
Every Wednesday you see whether Roivant Sciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies.
Show moreShow less
Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases.
The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases.
In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
Stock analysis
Roivant Sciences Ltd (ROIV) currently trades at $38.61, while our estimate is $19.47, 50% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $14.60 (bear) to $24.34 (bull), the price of $38.61 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Roivant Sciences Ltd reported revenue of $8.3M in FY2026 versus $55.3M in FY2022, a compound −37.8%/yr. Reported net income was −$300M in FY2026.
Key figures
Market cap $26.8B Large · EPS (TTM) $−0.6500 · Return on equity −8.5% · Return on assets (EBIT) −27.0% (5-year average) · Operating margin −3,226% · Revenue growth (YoY) +21.4% · EPS growth (YoY) −96.1% · Free cash flow −$759M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).
What moves the price
The share trades about 8% below its 52-week high and 92% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −50%, ROIV screens richer than that median.
Fair Value
Bear$14.60Fair Value $19.47Bull$24.34
Price $38.61 · Downside -49.6%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Quality Score breakdown
Overall quality44/100
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Profitability0
How much profit the company makes from its sales and capital
Quality Growth36
Are margins and returns getting better?
Cashflow33
Do the profits arrive as real cash?
Financial strength95
Debt, balance sheet and risk of trouble
Investment0
Does it invest with discipline instead of growing at any price?
Low Volatility38
How calm the share price moves, does not count
Price momentum79
Price momentum of the last 3 to 12 months, does not count
In the last 6 months, 7 officers or directors sold shares worth $255.1M and none bought.
SaleRichard PulikCFO2× since Dec 23, 2025: 706,731 shares, avg. $30.56$21.6MNov 11, 2026
SaleEric VenkerPresident & Immunovant CEO15× since Dec 9, 2025: 3,062,943 shares, avg. $31.01$95.0MNov 10, 2026
SaleEpperly Melissa BDirector4× since Mar 16, 2026: 82,299 shares, avg. $32.17$2.6MOct 1, 2026
SaleMeghan FitzgeraldDirector4× since Mar 26, 2026: 105,112 shares, avg. $31.13$3.3MSep 15, 2026
SaleMayukh SukhatmePresident & CIO, Director6× since Dec 17, 2025: 3,697,140 shares, avg. $29.52$109.1MAug 21, 2026
SaleQVT Financial LPDirector by Deputization4× since Nov 19, 2025: 5,658,561 shares, avg. $26.05$147.4MJun 30, 2026
SaleDaniel Allen GoldDirector4× since Nov 19, 2025: 5,658,561 shares, avg. $26.05$147.4MJun 30, 2026
SaleKeith S ManchesterDirector4× since Nov 19, 2025: 5,858,561 shares, avg. $26.37$154.5MJun 30, 2026
SaleMatthew GlineCEO, Director2× since Dec 15, 2025: 2,029,774 shares, avg. $22.75$46.2MApr 16, 2026
SaleJennifer HumesChief Accounting Officer13,538 shares at $28.37$384,073Apr 8, 2026
Plus 2 more entries from the last 12 months.
Plus 48 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−71.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−36.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−19.1%
Start year 2021 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.9%
’19
’20
’21
’22
’23
’24
’25
’26
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−4,500.5% (2021) → −15,560.6% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
News mood ⓘNews mood, the average tone of recent news (95 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Neutral
Recent news coverage is roughly neutral, about typical for how stocks are covered.
AI conclusion: Narrow moat early-stage biotech gains initial traction from its first approved product launch with encouraging uptake yet remains limited by deep operating losses and minimal evidence of durable advantage.
Main risk: Loss or adverse change in the licensing agreement with HanAll Biopharma could restrict development and commercialization of core candidates such as IMVT-1402 and batoclimab, hitting the pipeline and future revenue.
Bull case: Successful navigation of regulatory processes and retention of the HanAll licence could allow the Vant model and AI tools to accelerate additional indications and new assets, building a broader commercial portfolio.
Bear case: Repeated regulatory setbacks combined with any disruption to the HanAll licence or successful patent challenges could stall the pipeline, limit product exclusivity and prevent commercial revenue from covering ongoing development costs.
Roivant just launched its first approved product and early uptake looks encouraging. The initial sales, however, include pharmacy inventory builds that may create a modest headwind next quarter while the company keeps spending heavily across a wide pipeline. Will commercial traction from this drug and its follow-on indications grow fast enough to cover the costs before the cash runway tightens?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 848 stocks
Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation
Quality Score44 · Above median
Fair Value upside−49.6% · Bottom 25%
Profitability
Return on assets−5.2% · Above median
Growth and dividend
Revenue growth (quarter YoY)21.4% · Above median
Balance sheet
Debt / equity0.10× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B5.92× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 36
PAST (return on equity)0· sector 0
HEALTH (low debt)95· sector 96
DIVIDEND (yield)0· sector 20
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Roivant Sciences Ltd (ROIV) overvalued or undervalued?
As of Nov 14, 2026, our estimate of fair value is $19.47 versus a price of $38.61, about 50% lower (overvalued).
What is the fair value of ROIV?
Our estimate for Roivant Sciences Ltd is $19.47 (as of Nov 14, 2026), built from audited fundamentals. The current price: $38.61.
What is the quality score of ROIV?
Roivant Sciences Ltd has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Roivant Sciences Ltd (ROIV)?
Our calculated price target is the estimate of $19.47 (as of Nov 14, 2026). Cautious scenario $14.60, optimistic scenario $24.34. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Roivant Sciences Ltd stock forecast for 2026?
Our estimate puts fair value at $19.47, about 50% lower versus a price of $38.61 (overvalued). Cautious scenario $14.60, optimistic scenario $24.34. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Roivant Sciences Ltd (ROIV)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Roivant Sciences Ltd it is $19.47 per share (as of Nov 14, 2026), against a price of $38.61.
Is Roivant Sciences Ltd stock overvalued or undervalued in 2026?
As of Nov 14, 2026, ROIV trades above its calculated fair value: price $38.61, fair value $19.47, a gap of about −50% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ROIV?
No. The price is what the market pays today ($38.61); the fair value is what the company's own numbers justify ($19.47). For Roivant Sciences Ltd the two are $19.14 per share apart. That gap is exactly why we show both numbers side by side.
How much is Roivant Sciences Ltd worth?
The market values Roivant Sciences Ltd at about $26.8B (market capitalisation, as of Nov 14, 2026). Per share that is $38.61; our models calculate a fair value of $19.47 per share.
What do the bullish and bearish scenarios say about ROIV?
Our models span a range for Roivant Sciences Ltd: cautious scenario $14.60, base $19.47, optimistic $24.34 per share (as of Nov 14, 2026, price $38.61). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Roivant Sciences Ltd (ROIV)?
Balance-sheet figures for Roivant Sciences Ltd (as of Nov 14, 2026): return on equity −8.5%, debt of 0.10 per unit of equity. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is ROIV from its 52-week high?
Roivant Sciences Ltd trades at $38.61, about 8% below its 52-week high of $41.85 and 92% above the low of $20.10 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $19.47 is for.
Which stocks are comparable to Roivant Sciences Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Roivant Sciences Ltd stock attractive at the current price?
The data as of Nov 14, 2026: price $38.61, calculated fair value $19.47 (−50%), Quality Score 44/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Roivant Sciences Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Roivant Sciences Ltd (ROIV)?
The closing price on Nov 16, 2026 was $38.61. Our estimate is $19.47, about 50% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Roivant Sciences Ltd right now?
The price sits above even our optimistic bull case ($24.34). The favourable scenario is already priced in. Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Roivant Sciences Ltd
How large is the market capitalisation of Roivant Sciences Ltd (ROIV)?
The market capitalisation of Roivant Sciences Ltd is $26.8B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Roivant Sciences Ltd (ROIV)?
Earnings per share at Roivant Sciences Ltd are $−0.6500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Roivant Sciences Ltd (ROIV)?
The return on equity (ROE) of Roivant Sciences Ltd is −8.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Roivant Sciences Ltd (ROIV)?
On an EBIT basis the return on assets of Roivant Sciences Ltd is −27.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Roivant Sciences Ltd (ROIV)?
The operating margin of Roivant Sciences Ltd is −3,226% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Roivant Sciences Ltd (ROIV)?
Revenue at Roivant Sciences Ltd is growing 21.4% versus a year earlier (3y avg −36.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Roivant Sciences Ltd (ROIV)?
Earnings per share at Roivant Sciences Ltd are down 96.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Roivant Sciences Ltd (ROIV) generate?
The free cash flow of Roivant Sciences Ltd is −$759M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Roivant Sciences Ltd (ROIV) hold?
Roivant Sciences Ltd holds more cash than debt, $1.3B net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Roivant Sciences Ltd in the live analysis
One click puts Roivant Sciences Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.